4T1-luc2: An Orthotopic Mammary Cancer Model to Support Novel Immuno-Oncology Drug Discovery

Breast cancer is the second most deadly malignancy after lung cancer in woman in the United States, with an estimated 246,000 new cases and 40,450 deaths expected in 2016. Many treatment options for breast cancer exist including surgery, radiotherapy, anti-estrogen therapy, targeted therapies (e.g., trastuzumab), and chemotherapy. Despite these therapeutic advances, metastatic disease remains a […]

HT-29 as a Preclinical Model for Colorectal Cancer

In this model we have also evaluated the combination of radiation and gemcitabine (Figure 5) and illustrate the added benefit of the combination over either single agent treatment. Fig. 5: Subcutaneous Growth of HT-29 Following Combination Treatment with Localized Radiation and Gemcitabine Contact MI Bioresearch to discuss your next preclinical […]

786-O (pMMP-LucNeo) – A Model for Renal Cell Carcinoma

In an effort to address this unmet need, MI Bioresearch has developed an orthotopic RCC model, 786-O (pMMP-LucNeo) through implantation into the sub-renal capsule. This cell line has been transfected with luciferase, which allows for disease and response monitoring through bioluminescence imaging (BLI). In 786-O tumor bearing mice, we evaluated […]

5TGM1-luc – A Syngeneic Murine Model for Multiple Myeloma

The 5TGM1 multiple myeloma model arose spontaneously in aging C57BL/KaLwRij mice, and was propagated via serial passage in syngeneic mice prior to establishment of a cell line. MI Bioresearch’s 5TGM1 line has been luciferase-enabled to permit monitoring of growth in orthotopic sites such as the bone marrow by bioluminescent imaging […]

A549 – A Model for Non-Small Cell Lung Cancer

At MI Bioresearch we have been using A549 as a model of NSCLC for more than 10 years. We have run numerous studies in the subcutaneous setting with a number of standard agents. Above are some examples of response to paclitaxel (Figure 1) and docetaxel, bevacizumab and the combination (Figure […]

MDA-MB-231-luc-D3H2LN: A Valuable Model for Triple-Negative Breast Cancer Research

Fig 3:  MDA-MB-231-luc-D3H2LN Mammary Fat Pad Orthotopic Implant – Lymph Nodes MI Bioresearch has also validated MDA-MB-231-luc-D3H2LN as a metastatic bone model following an intracardiac injection. The MDA-MB-231-luc-D3H2LN cells naturally hone to the bone. Utilizing bioluminescence imaging will ensure that the injections are successful and that treatment groups can be […]

Comparison of Bioluminescence and MR Imaging to Evaluate Orthotopic Glioma Models

Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing glioma that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. These tumors are usually highly malignant because the cells reproduce quickly and they are supported by a large network of blood vessels. GBM is the […]

CT26: Murine Colon Carcinoma

CT26 and Flow Cytometry In addition to evaluating efficacy of anti-cancer drug combinations this model has proven useful in the assessment of phenotypic changes in the immune system. To this end we have evaluated CT26 tumors for a number of fundamental tumor infiltrating leukocytes with our Attune NxT® flow cytometer. […]

GL261: Syngeneic Murine Glioma Model

GL261 is one of the most frequently used syngeneic murine glioma models available. We capitalize on our state-of-the-art imaging capabilities to further interrogate the pharmacology of this model by utilizing a GL261 cell line that expresses luciferase (GL261-luc2, Caliper Life Sciences). This allows for longitudinal, in vivo visualization of the […]

MV(4;11): A Model of Human AML (acute myeloid leukemia)

Acute myeloid leukemia (AML) is a malignant disorder of the progenitor cells in myeloid hematopoiesis and represents a genetically heterogeneous cancer. The onset of AML is thought to require cooperation between active proliferation and defects in myeloid differentiation, which often results in chromosomal translocation (Gilliland et al., 2004). The annual incidence of AML is ~1.8 per […]